Background {#Sec1}
==========

Intrahepatic cholangiocarcinoma (ICC) rates have been rapidly increasing in the US since the mid-1980s.^[@CR1]^ Between 2001 and 2016, ICC rates among US women more than doubled (from 0.6 to 1.4/100,000 person-years, respectively).^[@CR2]^ ICC arises from cholangiocytes in the intrahepatic bile duct and is the second most common type of liver cancer in the US, accounting for 12% of primary liver cancers.^[@CR3]^

As cholangiocytes express both oestrogen receptor-α and -β,^[@CR4]--[@CR6]^ hormonal factors have been hypothesised to play a role in cholangiocarcinogenesis.^[@CR7]^ Experimental evidence suggests that oestrogen promotes cholangiocarcinogenesis, while selective oestrogen receptor modulators can inhibit growth.^[@CR8]--[@CR10]^ Additionally, a prior study from Khon Kaen, Thailand, reported higher circulating oestradiol in men with cholangiocarcinoma compared to controls.^[@CR11]^ Another recent study from the Liver Cancer Pooling Project (LCPP) reported that higher levels of circulating oestradiol in women were associated with an increased ICC risk.^[@CR12]^ Taken together, these results suggest that factors that affect oestrogenic regulation may play a role in the aetiology of ICC.

Several epidemiologic studies have examined exogenous hormone use and reproductive factors in relation to all primary liver cancer or hepatocellular carcinoma (HCC) risk,^[@CR7],[@CR13]^ but not ICC risk alone. One recent study from Sweden found that menopausal hormone therapy (MHT) use was associated with a lower risk of gastrointestinal cancers, but there were too few cases to examine the association with ICC as a unique outcome.^[@CR14]^ Thus, we conducted a prospective analysis of North American and European women to examine exogenous hormonal exposures and reproductive factors, as proxies of endogenous hormonal exposures, in relation to ICC risk.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

For this study, we combined the resources of the National Cancer Institute (NCI) Cohort Consortium and the UK Biobank. All North American-based cohort studies that are members of the NCI Cohort Consortium were invited to participate in the LCPP, as previously described.^[@CR13]^ For the current study, which is restricted to women, 12 cohorts contributed information on exogenous hormones and/or reproductive factors and ICC cases: NIH-AARP Diet and Health Study (AARP),^[@CR15]^ Agricultural Health Study (AHS),^[@CR16]^ The Breast Cancer Detection Demonstration Project (BCDDP),^[@CR17]^ Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO),^[@CR18]^ Women's Health Study (WHS),^[@CR19]^ New York University Women's Health Study (NYUWHS),^[@CR20]^ Cancer Prevention Study--II (CPS-II) Nutrition Cohort,^[@CR21]^ Iowa Women's Health Study (IWHS),^[@CR22]^ Black Women's Health Study (BWHS),^[@CR23]^ Women's Health Initiative (WHI),^[@CR24]^ Nurses' Health Study (NHS),^[@CR25]^ and the Canadian Study of Diet, Lifestyle, and Health (CSLDH)^[@CR26]^ (Supporting Table [S1](#MOESM1){ref-type="media"}). The Physicians' Health Study (PHS)^[@CR27]^ and Health Professionals Follow-Up Study (HPFS)^[@CR28]^ were excluded, as these cohorts only included men. The US Radiologic Technologists (USRT) Study^[@CR29]^ is also excluded, as this cohort had no women ICC cases. The UK Biobank is a large prospective cohort study that recruited over 500,000 men and women aged 40--69 years from one of 22 assessment centres located across England, Scotland and Wales between 2006 and 2010.^[@CR30]^ All studies participating in the LCPP contributed de-identified data following data sharing agreements between NCI and the cohort's academic institute; the UK Biobank was approved by the North West Multi-Centre Research Ethics Committee, and all participants provided written informed consent.

With the exception of the CSLDH, all other studies contributed the full cohort of individuals. For cost-efficiency, CSLDH was performed using a case-cohort design. Thus, from the entire cohort of women in CSLDH (*n* = 39,618) at baseline, an age-stratified random sample was selected to create a sub-cohort of women (*n* = 3224), which are utilised in analyses to represent the full cohort.^[@CR31]^ In total, 1,107,498 women participants were included: 851,157 women from the LCPP and 256,341 women from the UK Biobank.

Outcomes {#Sec4}
--------

Incident primary liver cancer (defined as International Classification of Diseases, 10th edition \[ICD-10\] diagnostic code C22) was ascertained by linkage to state-, provincial- or country-specific cancer registries or medical/pathology record review; dates of follow-up are given for each study in Supplemental Table [S1](#MOESM1){ref-type="media"}. Cases of ICC were classified using the ICD-O-3 morphology codes 8032--8033, 8041, 8050, 8070--8071, 8140--8141, 8160, 8260, 8480, 8481, 8490 and 8560. The current study included 237 ICC cases (LCPP *n* = 180 and UK Biobank *n* = 57) and 1,107,261 non-cases.

Exposures {#Sec5}
---------

In the LCPP, reproductive factors were self-reported via hard copy questionnaire and included age at menarche, parity, age at first birth, age at natural menopause, oophorectomy, fertile duration (years between menarche and menopause), oral contraceptive use, duration of oral contraceptive use, MHT use, recency of MHT use (never, current, former), duration of MHT use, type of MHT use (none, oestrogen-only MHT, oestrogen-progesterone combination MHT, other), and MHT route of administration (none, oral, non-oral). In the UK Biobank, the same exposures were assessed in a similar self-reported manner via touchscreen computerised and interviewer-administered questionnaires at baseline. The exception to similar exposure ascertainment is type of MHT, which was only asked of women who reported 'current' MHT use at baseline and was verified during a verbal interview with a UK Biobank nurse.

Statistical analysis {#Sec6}
--------------------

Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between exogenous hormone use and reproductive factors and risk of ICC. To account for the case-cohort design of CSLDH in the LCPP, all cases were weighted as one, and non-cases were weighted according to the inverse of their stratum-specific sampling fractions. All participants in the remaining cohorts were weighted as one using PROC SURVEYPHREG.^[@CR32]^ Follow-up of the analytic cohort occurred from time of exposure ascertainment until an event (i.e., incident ICC) or right-censoring (i.e., death, loss to follow-up, or last date of follow-up), whichever occurred first. The proportional hazards assumption was tested using an interaction between exogenous hormones or reproductive factors with log(time) in models that included confounders; no violations were observed (*p* \> 0.05). The adjusted study-specific effect estimates from the LCPP and the UK Biobank were combined using fixed-effects meta-analytic models.

Based on existing literature, LCPP models contained the following potential confounders:^[@CR33]^ age (continuous), alcohol consumption (g/day: none, ≤1.08, \>1.08--3.58, \>3.58--13.54, \>13.54), body mass index (BMI, \<25, 25--29.9, ≥30 kg/m^2^), diabetes (yes, no), race (white, other), smoking (never, former, current), parent cohort study, and education (\<high school, high school, some college/vocational, college, graduate degree). UK Biobank models contained age (continuous), alcohol consumption \[never, former, current light/occasional (\<16 g/day), current heavy (≥16 g/day)\], BMI (\<25, 25--29.9, ≥30 kg/m^2^), smoking (never, former, current), and education (\<secondary school, secondary school, college, graduate degree). Models using UK Biobank data were not adjusted for race, as almost 95% of the cohort is white, nor diabetes, as only one ICC case had a type 2 diabetes diagnosis. In the UK Biobank, medical history of hepatitis B and C virus (HBV/HCV) and cirrhosis were examined as potential covariates, but they did not alter the estimates and are not included in the final models (data not shown). Models examining reproductive factors also contained menopausal status (pre-, post-menopausal), while models examining menopausal factors (i.e., age at menopause and MHT use) were restricted to post-menopausal women. A lag analysis, excluding the first two years of follow-up, was performed to account for potential pre-existing liver disease. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and STATA version 14 (StataCorp LP, College Station, TX).

Nested case-control study of HBV/HCV {#Sec7}
------------------------------------

In the LCPP, 47 ICC cases that had a serum sample available were tested for determination of HBV and HCV serology status, in addition to 98 matched controls. To determine HBV status, hepatitis B surface antigen (HBsAg) was assayed using the Bio-Rad GS HBsAg 3.0 enzyme immunoassay (Bio-Rad Laboratories, Redmond, WA, USA). To determine HCV status, antibody to hepatitis C virus (anti-HCV) was assessed using the Ortho HCV Version 3.0 ELISA test system (Ortho-Clinical Diagnostics, Inc., Raritan, NJ, USA).

Results {#Sec8}
=======

Participants averaged 13.0 years of follow-up (maximum 30.4 years) in the LCPP and 5.5 years of follow-up (maximum 8.5 years) in the UK Biobank. Table [1](#Tab1){ref-type="table"} summarises women participant characteristics, which were similar between the LCPP and the UK Biobank. For example, the mean ages of non-cases were 57.7 and 56.1 and cases were 61.9 and 60.3 years, respectively. Among the non-cases, there was a similar prevalence of non-smokers (51.0 vs. 59.6%) and individuals with a BMI ≥ 30 kg/m^2^ (20.4 vs. 23.9%) in the LCPP and the UK Biobank, respectively. However, the LCPP had more post-menopausal non-cases (83.0 vs. 59.6%). In both the LCPP and the UK Biobank, ICC cases were more likely to be post-menopausal, to be current or past smokers, and to have a BMI ≥ 30 kg/m^2^.Table 1Characteristics of female participants in the Liver Cancer Pooling Project and the UK Biobank.Liver Cancer Pooling ProjectUK BiobankNo. non-cases (*N* = 850,977)No. ICC cases (*N* = 180)No. non-cases (*N* = 256,284)No. ICC cases (*N* = 57)No. (%)No. (%)No. (%)No. (%)Age at baseline, mean (SD)57.7 (10.56)61.9 (7.20)56.1 (0.02)60.3 (0.87)  \<50153,709 (18.1)9 (5.0)62,807 (24.5)5 (8.8)  50--59286,553 (33.7)52 (28.9)88,718 (34.6)19 (33.3)  60--69332,574 (39.1)97 (53.9)103,704 (40.5)31 (54.4)  ≥7078,141 (9.2)22 (12.2)1,055 (0.4)2 (3.5)Menopausal status  Pre-menopausal134,595 (15.8)9 (5.0)62,992 (24.6)4 (7.0)  Post-menopausal706,218 (83.0)171 (95.0)152,752 (59.6)41 (71.9)  Missing10,164 (1.2)0 (0.0)40,540 (15.8)12 (21.1)Alcohol intake  Liver Cancer Pooling Project   Non-drinker258,141 (30.3)48 (26.7)   Quartile 1: ≤1.08 g/day170,803 (20.1)41 (22.8)   Quartile 2: 1.09--3.58 g/day152,765 (18.0)32 (17.8)   Quartile 3: 3.59--13.54 g/day129,502 (15.2)29 (16.1)   Quartile 4: \>13.54 g/day98,621 (11.6)21 (11.7)   Missing41,145 (4.8)9 (5.0)  UK Biobank   Never15,072 (5.9)4 (7.0)   Current (\<16 g/day)167,319 (65.3)39 (68.4)   Current (≥16 g/day)62,762 (24.5)10 (17.5)   Former9251 (3.6)4 (7.0)   Missing1,880 (0.7)0 (0.0)Smoking status  Never434,198 (51.0)80 (44.4)152,637 (59.6)20 (35.1)  Former284,799 (33.5)75 (41.7)79,316 (30.9)29 (50.9)  Current114,922 (13.5)23 (12.8)22,922 (8.9)8 (14.0)  Missing17,058 (2.0)2 (1.1)1409 (0.6)0 (0.0)BMI status (kg/m^2^)  \<25387,573 (45.5)59 (32.8)101,363 (39.6)22 (38.6)  25--29.9260,561 (30.6)67 (37.2)92,241 (36.0)20 (35.1)  ≥30173,376 (20.4)45 (25.0)61,324 (23.9)15 (26.3)  Missing29,467 (3.5)9 (5.0)1,356 (0.5)0 (0.0)Diabetes  No792,844 (93.2)159 (88.3)247,484 (96.6)56 (98.3)  Yes45,678 (5.4)18 (10.0)8800 (3.4)1 (1.7)  Missing12,455 (1.5)3 (1.7)0 (0.0)0 (0.0)Race  White715,739 (84.1)156 (86.7)  Black93,734 (11.0)9 (5.0)  Asian/Pacific Islander11,297 (1.3)4 (2.2)  American Indian/Alaskan Native2,032 (0.2)0 0.0  Other19,336 (2.3)7 (3.9)  Missing8,839 (1.0)4 (2.2)Education  High School or Less45,659 (5.4)12 (6.7)  High School184,586 (21.7)32 (17.8)73,038 (28.5)10 (17.5)  Some College/Vocational257,563 (30.3)59 (32.8)  College Degree190,027 (22.3)44 (24.4)41,596 (16.2)8 (14.0)  Graduate Degree135,288 (15.9)25 (13.9)94,233 (36.8)18 (31.6)  None of the above42,439 (16.6)20 (35.1)  Missing37,854 (4.4)8 (4.4)4978 (1.9)1 (1.8)

As shown in Table [2](#Tab2){ref-type="table"}, there were null associations between age at menarche, parity, or age at first birth and risk of ICC. Similarly, there was a null association with ever use of oral contraceptives (HR = 1.12, 95% CI: 0.82--1.53). However, examining duration of oral contraceptive use, nine or more years of use was associated with 62% increased risk of ICC in the combined study population (HR = 1.62, 95% CI: 1.03--2.55), which was in the same direction in both LCPP (HR = 1.71, 95% CI: 1.01--2.89) and UK Biobank cohorts (HR = 1.38, 95% CI: 0.56--3.39).Table 2Association between reproductive factors and intrahepatic cholangiocarcinoma in the Liver Cancer Pooling Project and the UK Biobank.Liver Cancer Pooling ProjectUK BiobankCombinedReproductive FactorsNo. non-cases (*N* = 722,150)^a^No. ICC Cases (*N* = 154)^a^HR^b^95% CINo. non-cases (*N* = 209,464)^a^No. ICC Cases (*N* = 44)^a^HR^c^95% CIHR95% CIAge at menarche  \<12207,89349Referent39,2154ReferentReferent  12--13366,443720.730.50--1.0789,034232.590.89--7.510.840.59--1.20  14+133,893290.760.48--1.2075,233161.830.61--5.520.870.57--1.32  Missing13,92145,9821  *  p* for trend0.720.36Ever had children  No98,30420Referent40,2056ReferentReferent  Yes611,8751340.870.54--1.39169,121381.140.47--2.730.920.61--1.41  Missing11,97101380Number of children  097,65120Referent40,2056ReferentReferent  178,487120.670.33--1.3728,18271.370.46--4.090.830.46--1.50  2185,348380.830.48--1.4491,323181.050.41--2.670.880.55--1.41  3+345,531830.820.50--1.3549,752131.160.43--3.130.880.56--1.37  Missing15,133100  *  p* for trend0.970.35Age at first birth (parous women)  \<21105,54419Referent19,7345ReferentReferent  21--24275,185721.310.77--2.2140,40780.880.28--2.731.220.75--1.98  25--28147,059250.740.39--1.3944,89091.260.40--3.950.840.48--1.47  ≥2959,050151.020.49--2.1135,66991.870.57--6.161.210.65--2.25  Missing135,3122328,4197  *  p* for trend0.620.90Oral contraceptive use  No384,69997Referent39,0959ReferentReferent  Yes331,664571.060.75--1.48169,887351.460.68--3.161.120.82--1.53  Missing5,78704800Duration of oral contraceptive use  None384,69997Referent39,0959ReferentReferent  \<1 year66,782120.940.52--1.697,03921.550.33--7.241.000.58--1.74  1--2.5 years77,857121.090.59--2.0117,99930.920.25--3.451.060.61--1.84  2.5--6 years50,17650.590.24--1.4922,06972.000.72--5.511.010.51--1.98  6--9 years70,620111.000.54--1.8822,27730.940.25--3.590.990.57--1.73  9+ years61,781171.711.01--2.8978,287141.380.56--3.391.621.03--2.55  Missing10,235022,6966  *  p* for trend0.140.46^a^Numbers are for women with non-missing covariates.^b^Adjusted for age (continuous), alcohol (g/day: none, ≤1.08, \>1.08--3.58, \>3.58--13.54, \>13.54), BMI (kg/m^2^: \<25, 25--29.9, ≥30), diabetes (yes, no), race (white, other), smoking (never, former, current), parent cohort study, menopausal status (pre-, post-menopausal), and education (\<high school, high school, some college/vocational, college, graduate degree).^c^Adjusted for age (continuous), alcohol (never, former, current light/occasional (\<16 g/day), current heavy (≥16 g/day)), BMI (kg/m^2^: \<25, 25--29.9, ≥30), smoking (never, former, current), menopausal status (pre-, post-menopausal), and education (\<secondary school, secondary school, college, graduate degree).

There was no association with age at natural menopause, but there was a 2-fold increased risk of ICC associated with hysterectomy (HR = 1.98, 95% CI: 1.27--3.09), compared to women aged 50--54 at natural menopause, which was driven by the results from the LCPP (HR = 2.25, 95% CI: 1.38--3.65; Table [3](#Tab3){ref-type="table"}). Further adjustment in the LCPP for MHT use did not substantially affect the estimate (HR = 2.15, 95% CI: 1.31--3.52), although women with hysterectomy were more likely to report MHT use---especially oestrogen-only MHT (Supplemental Table [S2](#MOESM1){ref-type="media"}). There was no association with total fertile duration. Examining MHT use, including recency, duration, or route of administration, revealed no associations with ICC risk. However, there was a possible indication of increased risk of ICC and oestrogen-only therapy in post-menopausal women (HR = 1.44, 95% CI: 0.91--2.28).Table 3Associations between menopausal factors and menopausal hormone therapy (MHT) use among post-menopausal women and risk of intrahepatic cholangiocarcinoma in the Liver Cancer Pooling Project and the UK Biobank.Liver Cancer Pooling ProjectUK BiobankCombinedAge at menopauseNo. non-Cases (*N* = 722,150)^a^No. ICC Cases (*N* = 154)^a^HR^b^95% CINo. non-Cases (*N* = 209,464)^a^No. ICC Cases (*N* = 44)^a^HR^c^95% CIHR95% CINatural menopause  \<4535,74570.820.37--1.8111,273141.210.38--3.840.930.48--1.79  45--4989,227150.680.38--1.2329,13740.620.21--1.770.670.40--1.11  50--54159,70642Referent63,253ReferentReferent  ≥5535,00170.670.30--1.4920,11471.530.61--3.850.960.52--1.75  *  p* for trend0.840.59Surgical menopause  Bilateral oophorectomy^d^54,645120.840.43--1.636870----  Hysterectomy^d^100,694362.251.38--3.6515,80951.110.39--3.131.981.27--3.09  Missing131,1733078375Fertile Duration All women, per year increase341,659801.020.97--1.07135,777340.970.91--1.031.000.96--1.04Menopausal hormone therapy (MHT)  Never259,83365Referent136,84923ReferentReferent  Ever use340,563831.120.80--1.5672,057211.050.56--1.961.100.82--1.49  Missing5,79515560Timing of use  Never241,74663Referent136,84923ReferentReferent  Former81,684220.920.56--1.5063,593191.050.55--2.010.970.65--1.43  Current227,895591.260.87--1.84846421.040.24--4.471.250.87--1.78  Missing54,86655560Duration of use  None130,54936Referent136,84923ReferentReferent  \<5 years55,378110.790.42--1.5223,84550.840.31--2.260.800.47--1.37  5--9 years37,442121.300.66--2.5516,45220.450.10--1.971.090.59--2.02  10+ years66,548160.720.35--1.4713,71771.530.62--3.760.970.55--1.70  Missing231,4995818,5997  *  p* for trend0.640.05MHT type^e^ None153,76035Referent136,84923ReferentReferent  Oestrogen only125,090381.440.90--2.31270811.450.1910.851.440.91--2.28  Combination100,318221.010.58--1.76573510.790.11--5.950.990.58--1.69  Other MHT15,98210.340.05--2.54  Missing196,8444464,14919MHT pill usage^e^  None87,96624Referent136,84923ReferentReferent  Used pills118,376361.060.63--1.796,50121.340.31--5.761.090.67--1.78  Other MHT8,46710.550.07--4.1018790--  Missing377,1857964,23319^a^Numbers are for women with non-missing covariates.^b^Adjusted for age (continuous), alcohol (g/day: none, ≤1.08, \>1.08--3.58, \>3.58--13.54, \>13.54), BMI (kg/m^2^: \<25, 25--29.9, ≥30), diabetes (yes, no), race (white, other), smoking (never, former, current), parent cohort study, menopausal status (pre-, post-menopausal), and education (\<high school, high school, some college/vocational, college, graduate degree).^c^Adjusted for age (continuous), alcohol (never, former, current light/occasional (\<16 g/day), current heavy (≥16 g/day)), BMI (kg/m^2^: \<25, 25--29.9, ≥30), smoking (never, former, current), menopausal status (pre-, post-menopausal), and education (\<secondary school, secondary school, college, graduate degree).^d^Reference group for oophorectomy and hysterectomy is females who had natural menopause aged between 50 and 54 years old.^e^Information on MHT type and pill usage only available for current MHT users at baseline in the UK Biobank.

Among the 47 ICC cases and 98 controls evaluated for HBV and HCV infections, one case (2.1%) and no controls were positive for HBsAg. For anti-HCV, no cases and three controls (3.1%) were positive. The viral results were not incorporated into the main analyses, as the results were only available for a small proportion of LCPP participants. In sensitivity analyses that dropped HBsAg(+) and anti-HCV(+) cases, the results did not differ from the analyses that included all cases (data not shown). Similarly, analyses that removed cases that developed in the first two years of follow-up were similar to those presented (data not shown).

Discussion {#Sec9}
==========

In the present study, long-term oral contraceptive use was associated with a 62% increased ICC risk, and hysterectomy was associated with a doubling of risk. The other reproductive factors were not associated with risk of ICC.

This is the first study to date to examine exogenous hormone use, reproductive factors and ICC risk. Prior studies have been limited to examination of all primary liver cancer or HCC only, which is the dominant form of liver cancer and accounts for 75% of primary liver cancer cases.^[@CR7]^ Thus, all prior examinations of exogenous hormone use and reproductive risk factors for liver cancer have been primarily driven by the aetiology of HCC. However, we discuss these prior results herein to highlight the similarities and differences in the aetiology of these two types of liver cancer. HCC is 2--3 times more common among men than women,^[@CR34]^ while incidence rates of ICC are only 30% higher in men than in women.^[@CR35]^ Reasons for reduced sex differences in ICC risk are unclear, but may be partially explained by oestrogenic factors increasing risk in women, as reported in the current study.

In 1999, the International Agency for Research on Cancer (IARC) concluded that there was sufficient evidence that oral contraceptives increased risk of liver cancer in the absence of viral infections.^[@CR36]^ However, a meta-analysis reported a 55% increased risk of liver cancer only in case-control studies, but no association in cohort studies.^[@CR37]^ The most recent 2018 IARC monograph concluded that there was still sufficient evidence that oestrogen-progesterone combination oral contraceptives cause liver cancer.^[@CR38]^ While the recent IARC monograph acknowledged that there was no association found in cohort studies, the majority of these to-date have included small numbers of cases. The prior study of HCC in the LCPP showed an increased, but non-significant, risk of HCC with more than 6 years of oral contraceptive use,^[@CR39]^ which is similar to the significant increased risk of ICC reported herein for nine or more years of oral contraceptive use.

The reported associations between MHT use and primary liver cancer risk have been inconsistent. A recent meta-analysis reported that MHT was associated with a 40% decreased risk of primary liver cancer across five studies.^[@CR40]^ Inverse associations were also reported for oestrogen-only, as well as oestrogen-progesterone combination MHT. However, there was significant heterogeneity between the studies in the meta-analysis. One of these studies examined MHT from prescription records and reported a 42% decreased risk of liver cancer.^[@CR41]^ However, none of these studies were able to examine ICC independent of primary liver cancer. Our study reported that oestrogen-only MHT use in post-menopausal women was associated with a possible indication of increased risk of ICC, albeit non-significant, which was consistent in the cohorts in North America and the UK. However, the sample size was limited, and the UK Biobank only assessed type of MHT for women who reported 'current' MHT use at time of the questionnaire.

Experimental evidence suggests that oestrogen, potentially mediated through interleukin-6 (IL-6)^[@CR10]^ or vascular endothelial growth factor (VEGF),^[@CR8]^ promotes cholangiocarcinogenesis, while selective oestrogen receptor modulators can inhibit growth.^[@CR8]--[@CR10]^ Cholangiocytes can express both oestrogen receptor (ER)-α and -β, whereas hepatocytes express only ER-α.^[@CR42]^ In bile duct ligated rats, ER-β increased 5-fold in cholangiocytes, whereas ER-α decreased in both cholangiocytes and hepatocytes.^[@CR42]^ Thus, the increased risk of ICC associated with oestrogen-only MHT use is biologically plausible through modulation of cholangiocyte proliferation.^[@CR43],[@CR44]^ While statistical power was still somewhat limited to examine this hypothesis, both the LCPP and the UK Biobank reported nearly identical effect estimates for the oestrogen-only MHT---ICC association.

In epidemiologic investigations of circulating sex steroid hormones and ICC risk, two studies have reported higher levels of circulating oestradiol in both men and women cholangiocarcinoma cases compared to controls.^[@CR11],[@CR12]^ One of these studies was based in the LCPP and reported that a doubling of circulating oestrogen levels in women was associated with a 40% increased ICC risk.^[@CR12]^ Neither study reported associations with circulating androgen levels.

Of the reproductive factors, which have been utilised as proxies of hormone status, parity is the most well studied in relation to primary liver cancer but there is significant heterogeneity in results. A recent meta-analysis reported a non-linear association, with a J-shaped relationship between parity and primary liver cancer.^[@CR40]^ This restricted cubic spline model suggested that risk of primary liver cancer began to increase with more than five live births. Little to no association has been reported with age at menarche, age at first birth and age at menopause. However, two studies have reported oophorectomy is associated with an increased risk of HCC.^[@CR39],[@CR45]^ Similarly, in two recent studies, medically recorded bilateral oophorectomy was associated with a 30--70% increased risk of non-alcoholic fatty liver disease.^[@CR46],[@CR47]^ While the current study did not find an association with oophorectomy, there was an increased risk of ICC associated with hysterectomy. This could be due either to misclassified self-reported hysterectomy and oophorectomy status,^[@CR48]^ whereby women that had an oophorectomy tend to misreport (i.e., report hysterectomy instead of oophorectomy), or to alterations in sex steroid hormones, particularly decreased androgen levels, in hysterectomised women.^[@CR49]^ Additionally, women undergoing hysterectomy may be more likely to begin taking MHT.^[@CR50]^ We also report that MHT use, in particular oestrogen-only MHT use, is more common among women who report hysterectomy than in those who report natural menopause. However, the LCPP does not have information on age at hysterectomy. In the UK Biobank, only 26% of participants started taking MHT after hysterectomy (7% within 1-year post-hysterectomy); thus, MHT initiation is not strongly related to hysterectomy. Further, adjustment for MHT use did not substantially change the hysterectomy-ICC association. Alternatively, hysterectomy, which has been associated with weight gain and diabetes, may have indirect effects on ICC risk.^[@CR51],[@CR52]^ In a recent meta-analysis, we reported that excess adiposity and diabetes were both associated with a 50% increased ICC risk.^[@CR53]^ Thus, hysterectomy could be leading to weight gain or development of diabetes in women that places them at higher ICC risk.

The current report is the first study focused specifically on reproductive factors and ICC. The large population of over 1.1 million women available from combining the LCPP and the UK Biobank allowed for investigation of reproductive factors and exogenous hormonal exposures in relation to ICC risk, which is a rare tumour with incidence rates typically 1.0/100,000 or less. Further, as the baseline enrolment for cohorts in the LCPP was 1980--1998 and in the UK Biobank was 2006--2010, the associations reported in both studies suggest that secular trends did not have influential effects. This study included a wide geographic representation from North America and the UK. Additionally, the prospective design minimises recall bias. In addition, sensitivity analyses that excluded ICCs that developed in the first two years of follow-up supported the results of the main analysis.

Limitations include exposure capture, risk factor information, and generalisability. All exposures in the included cohorts were self-reported. Thus, some of the exposures, for example oophorectomy, may not be reported accurately compared to medical report. However, the majority of studies to date have relied on self-reported data. In particular, for oral contraceptive use, there are not currently good resources with prescription information and sufficient follow-up for any liver cancer outcome. Formulations of oral contraceptives have changed over time, which makes examining and definitively addressing the association between oral contraceptive use and ICC challenging. Additionally, there was no information on specific MHT formulations, and for the UK Biobank, type of MHT used was only available for women currently reporting MHT use at the time of questionnaire administration. As serum or plasma samples were only available for a small number of ICC cases, we were unable to include HBV or HCV as potential covariates. However, the prevalence of HBV and HCV in the general population of women in the US and UK is exceedingly low (≤1%).^[@CR54]--[@CR56]^ Further, the UK Biobank is in the process of testing all participants for viral factors but the data are not yet publicly available. As these cohorts were established to examine all cancer types, and not specifically liver cancer, there is no information on pre-existing liver disease among the participants in the LCPP. Models are adjusted for diabetes, but diabetes type (1 or 2) is not captured in the majority of LCPP cohorts. However, type 2 diabetes accounts for 95% of diabetes diagnoses.^[@CR57]^ As this is an older population, diabetes is utilised as a proxy of type 2 diabetes. Finally, this is a population of primarily white post-menopausal women. Thus, the generalisability of these results to other racial/ethnic groups may not be assumed.

In summary, we report that long-term oral contraceptive use and hysterectomy are associated with an increased risk of ICC. Other reproductive factors were unrelated to risk. While intriguing, replication of these findings is warranted, ideally in populations with medical record data to avoid potential misclassification of exposures.

Supplementary information
=========================

 {#Sec10}

Supplemental Tables S1 and S2

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Jessica L. Petrick, Úna C. McMenamin

Supplementary information
=========================

**Supplementary information** is available for this paper at 10.1038/s41416-020-0835-5.

For the Black Women's Health Study, pathology data were obtained from several of the following state cancer registries (AZ, CA, CO, CT, DE, DC, FL, GA, IL, IN, KY, LA, MD, MA, MI, NJ, NY, NC, OK, PA, SC, TN, TX, VA), and results reported do not necessarily represent their views. For the Nurses' Health Study and the Health Professionals Follow-up Study, we would like to thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. We assume full responsibility for analyses and interpretation of these data. For NIH-AARP, the acknowledgement can be found at the following website: <https://dietandhealth.cancer.gov/acknowledgement.html>. For the Women's Health Initiative, the full list of investigators that have contributed can be found on the following website: <https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf>. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. We would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the National Cancer Institute's Surveillance Epidemiology and End Results Program.

Study concept and design, acquisition of data, analysis and interpretation of data, drafting of the paper, critical revision of the paper for important intellectual content, and statistical analysis: J.L.P. and Ú.C.M.; interpretation of data and critical revision of the paper for important intellectual content: B.I.G.; design and collection data from individual cohort studies, design of the consortium, interpretation of data, and critical revision of the paper for important intellectual content: X.Z., A.Z-J., J.W-W., T.G.S., R.S., H.D.S., C.S., L.R., T.E.R., K.R., M.P.P., J.N.P., J.R.P., Y.L., M.S.L., L.M.L., I-M.L., J.K., C.M.K., V.A.K., J.N.H., E.G., J.M.G., S.M.G., N.D.F., A.A.F., D.Q.C., Y.C., A.T.C., J.E.B., L.E.B, J.W.B., C.R.C., P.T.C.; concept and design of the consortium, collection of data for the consortium, analysis and interpretation of data, and critical revision of the paper for important intellectual content: K.A.M. All authors approved the final draft submitted.

In the LCPP, the individual cohorts were approved by the institutional review boards of the participating institutions; the LCPP was approved by the NIH Office of Human Subjects Research. The UK Biobank was approved by the North West Multi-Centre Research Ethics Committee. All participants provided written informed consent, and the study was performed in accordance with the Declaration of Helsinki.

Data can be obtained for legitimate research purposes. Access to LCPP data can be provided by submitting a request to Katherine McGlynn (mcglynnk\@mail.nih.gov) or Peter Campbell (peter.campbell\@cancer.org). UK Biobank data can be provided by submitting an application to the UK Biobank (<https://www.ukbiobank.ac.uk/>).

The authors declare no competing interests.

Access to the UK Biobank was funded by a Cancer Research UK Population Research Postdoctoral Fellowship (Ú.C.M.). NIH Intramural Research Program, National Cancer Institute (J.L.P., A.A.F., L.E.B.F., J.N.H., C.M.K., N.D.F., B.I.G., J.K., L.M.L., M.S.L., M.P.P., C.S., R.S., K.A.M.). National Institutes of Health grants CA047988 (I.L., J.E.B.), CA182913 (I.L., J.E.B.), HL043851 (I.L., J.E.B.), HL080467 (I.L., J.E.B.), HL099355 (I.L., J.E.B.), K07 CA188126 (X.Z.), DK098311 (A.T.C.), CA186107 (A.T.C.), CA87969 (A.T.C.), CA167552 (A.T.C.), P30 CA016087 (A.Z-J.), P30 ES000260 (A.Z-J.), UM1 CA164974 (L Rosenberg, JR Palmer), R01 CA058420 (L.R., J.R.P.), and R01 CA39742 (K.R., J.N.P.). American Cancer Society Research Scholar Grant RSG NEC-130476 (X.Z.). The WHI program (J.W-W., T.E.R., Y.L., J.W.B.) is funded by the National Institutes of Health contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C and HHSN268201600004C. The HPFS and NHS programs (X.Z.) were support by the National Cancer Institute, National Institutes of Health grant numbers UM1CA186107, P50CA127003, P01CA87969 and UM1CA167552.
